sellWeak cluster of 510b5-1 plan
Matthew Shair sold $820k of NUVL
director at Nuvalent, Inc.. 7,500 shares at an average of $109.37, traded Nov 24, 2025, filed Nov 26, 2025.
Warning score
32Value
$820k
7,500 shares
Holdings after
201,672
-1% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleDirector
- +22Trade size$820k at market
- 0Share of holdings soldSold 0.5% of holdings
- +15Cluster5 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001193125-25-300638, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 24, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -369 | $107.70 | $40k | 1,382,675 | Nov 26, 2025 |
| Nov 24, 2025 | SOpen-market sale Class A Common Stockindirect: See Footnote10b5-1 | -104 | $107.70 | $11k | 203,218 | Nov 26, 2025 |
| Nov 24, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -2,262 | $108.73 | $246k | 1,380,413 | Nov 26, 2025 |
| Nov 24, 2025 | SOpen-market sale Class A Common Stockindirect: See Footnote10b5-1 | -638 | $108.73 | $69k | 202,580 | Nov 26, 2025 |
| Nov 24, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -2,026 | $109.77 | $222k | 1,378,387 | Nov 26, 2025 |
| Nov 24, 2025 | SOpen-market sale Class A Common Stockindirect: See Footnote10b5-1 | -572 | $109.77 | $63k | 202,008 | Nov 26, 2025 |
| Nov 24, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -1,193 | $110.42 | $132k | 1,377,194 | Nov 26, 2025 |
| Nov 24, 2025 | SOpen-market sale Class A Common Stockindirect: See Footnote10b5-1 | -336 | $110.42 | $37k | 201,672 | Nov 26, 2025 |
Related signals
Other insiders at Nuvalent, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | Nuvalent, Inc. | Henry E. Pelish Chief Scientific Officer | $261k 2,111 shares | -3% | |
| 30Weak | Nuvalent, Inc. | James Richard Porter President and CEO | $3.7M 30,000 shares | -8% | |
| 32Weak | Nuvalent, Inc. | Alexandra Balcom Chief Financial Officer | $1.4M 11,430 shares | -12% | |
| 30Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $2.8M 23,000 shares | -28% | |
| 16Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $679k 5,500 shares | -9% | |
| 30Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $2.5M 20,000 shares | -26% | |
| 30Weak | Nuvalent, Inc. | James Richard Porter President and CEO | $2.7M 30,000 shares | -8% | |
| 32Weak | Nuvalent, Inc. | Alexandra Balcom Chief Financial Officer | $1.1M 11,430 shares | -12% | |
| 14Weak | Nuvalent, Inc. | Deborah Ann Miller Chief Legal Officer | $593k 5,500 shares | -8% | |
| 14Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $593k 5,500 shares | -9% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.